- Home
- TGTX
TGTX
TG Therapeutics Inc.
as 12-18-2024 10:00am EST
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.
| Founded: | 1993 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 5.4B | IPO Year: | 1995 |
| Target Price: | $40.67 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.84 - $36.84 | Next Earning Date: | 11-04-2024 |
| Revenue: | $264,790,000 | Revenue Growth: | 39.53% |
| Revenue Growth (this year): | 43.74% | Revenue Growth (next year): | 64.30% |
Stock Insider Trading Activity of TG Therapeutics Inc. (TGTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Charney Laurence N | TGTX | Director | Nov 11 '24 | Sell | $30.20 | 25,000 | $754,875.00 | 212,479 | |
| Lonial Sagar | TGTX | Director | Nov 11 '24 | Sell | $30.44 | 5,000 | $152,200.00 | 100,195 | |
| Echelard Yann | TGTX | Director | Nov 5 '24 | Sell | $24.48 | 20,000 | $489,600.00 | 224,098 |
Latest TG Therapeutics Inc. News
TGTX Breaking Stock News: Dive into TGTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
High Growth Tech Stocks To Watch In The United States
Argus Research
8 days ago
TGTX: Lowering target price to $33.00
Argus Research
15 days ago
TGTX: Lowering target price to $35.00
GlobeNewswire
19 days ago
TG Therapeutics to Participate in the Evercore HealthCONx Conference
TipRanks
22 days ago
TG Therapeutics price target raised to $43 from $30 at JPMorgan
GuruFocus.com
a month ago
TG Therapeutics Stock Soars Nearly 15% After Topping Deloitte's Fast 500 and Raising Revenue Outlook
GlobeNewswire
a month ago
TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
Argus Research
a month ago
TGTX: Raising target price to $32.00
Compare TGTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TGTX TG Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.